25 XP   0   0   10

Citius Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Citius Pharmaceuticals Inc together

PenkeI guess you are interested in Citius Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Citius Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Citius Pharmaceuticals Inc

I send you an email if I find something interesting about Citius Pharmaceuticals Inc.

Quick analysis of Citius Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Citius Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.54
Expected worth in 1 year
$0.44
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.10
Return On Investment
-14.2%

For what price can you sell your share?

Current Price per Share
$0.69
Expected price per share
$0.6 - $1.07
How sure are you?
50%

1. Valuation of Citius Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$0.69

Intrinsic Value Per Share

$-2.40 - $0.21

Total Value Per Share

$-1.87 - $0.75

2. Growth of Citius Pharmaceuticals Inc (5 min.)




Is Citius Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$85.3m$108.2m-$16.5m-18.0%

How much money is Citius Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.5m-$6.9m-$2.5m-26.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Citius Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#402 / 1008

Most Revenue
#977 / 1008

Most Profit
#575 / 1008

Most Efficient
#412 / 1008

What can you expect buying and holding a share of Citius Pharmaceuticals Inc? (5 min.)

Welcome investor! Citius Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Citius Pharmaceuticals Inc.

What can you expect buying and holding a share of Citius Pharmaceuticals Inc?

First you should know what it really means to hold a share of Citius Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Citius Pharmaceuticals Inc is $0.6947. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Citius Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Citius Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.54. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Citius Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.06-8.4%-0.06-8.6%-0.04-6.3%-0.04-5.8%-0.03-3.8%
Usd Book Value Change Per Share-0.04-5.5%-0.02-3.6%-0.04-5.3%0.022.8%0.011.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-5.5%-0.02-3.6%-0.04-5.3%0.022.8%0.011.9%
Usd Price Per Share0.76-0.95-1.18-1.27-1.30-
Price to Earnings Ratio-3.26--4.01--7.08--9.01--19.25-
Price-to-Total Gains Ratio-19.74--6.59--35.94-2.32--177.79-
Price to Book Ratio1.41-1.64-1.71-3.84--5.65-
Price-to-Total Gains Ratio-19.74--6.59--35.94-2.32--177.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.6947
Number of shares1439
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.02
Usd Total Gains Per Share-0.020.02
Gains per Quarter (1439 shares)-35.5027.66
Gains per Year (1439 shares)-142.00110.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-142-1520111101
20-284-2940221212
30-426-4360332323
40-568-5780443434
50-710-7200553545
60-852-8620664656
70-994-10040774767
80-1136-11460885878
90-1278-12880996989
100-1420-1430011061100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.051.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%13.027.00.032.5%15.034.02.029.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.051.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%13.027.00.032.5%15.034.02.029.4%

Fundamentals of Citius Pharmaceuticals Inc

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Fundamental data was last updated by Penke on 2024-05-02 15:10:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Citius Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Citius Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Citius Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--213.0%+213.0%
YOY--278.4%+278.4%
5Y--426.2%+426.2%
10Y--593.8%+593.8%
1.1.2. Return on Assets

Shows how efficient Citius Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • -9.5% Return on Assets means that Citius Pharmaceuticals Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Citius Pharmaceuticals Inc:

  • The MRQ is -9.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-9.2%-0.3%
TTM-9.2%YOY-5.9%-3.4%
TTM-9.2%5Y-10.1%+0.8%
5Y-10.1%10Y-33.9%+23.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-12.9%+3.4%
TTM-9.2%-12.2%+3.0%
YOY-5.9%-11.2%+5.3%
5Y-10.1%-13.5%+3.4%
10Y-33.9%-15.0%-18.9%
1.1.3. Return on Equity

Shows how efficient Citius Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • -10.9% Return on Equity means Citius Pharmaceuticals Inc generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Citius Pharmaceuticals Inc:

  • The MRQ is -10.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.9%TTM-10.5%-0.4%
TTM-10.5%YOY-6.4%-4.1%
TTM-10.5%5Y-12.1%+1.5%
5Y-12.1%10Y-10.4%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.9%-16.3%+5.4%
TTM-10.5%-15.7%+5.2%
YOY-6.4%-14.1%+7.7%
5Y-12.1%-18.7%+6.6%
10Y-10.4%-19.6%+9.2%

1.2. Operating Efficiency of Citius Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Citius Pharmaceuticals Inc is operating .

  • Measures how much profit Citius Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Citius Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.8%+299.8%
TTM--226.2%+226.2%
YOY--287.3%+287.3%
5Y--456.6%+456.6%
10Y--593.3%+593.3%
1.2.2. Operating Ratio

Measures how efficient Citius Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Citius Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.238-3.238
TTM-3.283-3.283
YOY-3.742-3.742
5Y-5.555-5.555
10Y-7.364-7.364

1.3. Liquidity of Citius Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Citius Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.06 means the company has $5.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Citius Pharmaceuticals Inc:

  • The MRQ is 5.057. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.931. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.057TTM5.931-0.874
TTM5.931YOY11.261-5.330
TTM5.9315Y8.866-2.935
5Y8.86610Y4.856+4.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0573.828+1.229
TTM5.9314.158+1.773
YOY11.2615.314+5.947
5Y8.8666.101+2.765
10Y4.8566.448-1.592
1.3.2. Quick Ratio

Measures if Citius Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.65 means the company can pay off $3.65 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Citius Pharmaceuticals Inc:

  • The MRQ is 3.647. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.664. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.647TTM4.664-1.017
TTM4.664YOY10.493-5.828
TTM4.6645Y8.345-3.681
5Y8.34510Y4.584+3.760
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6473.470+0.177
TTM4.6643.991+0.673
YOY10.4935.371+5.122
5Y8.3456.070+2.275
10Y4.5846.441-1.857

1.4. Solvency of Citius Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Citius Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Citius Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Citius Pharmaceuticals Inc assets are financed with 12.4% credit (debt) and the remaining percentage (100% - 12.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Citius Pharmaceuticals Inc:

  • The MRQ is 0.124. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.118. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.124TTM0.118+0.006
TTM0.118YOY0.087+0.031
TTM0.1185Y0.133-0.015
5Y0.13310Y0.746-0.613
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1240.349-0.225
TTM0.1180.340-0.222
YOY0.0870.273-0.186
5Y0.1330.368-0.235
10Y0.7460.388+0.358
1.4.2. Debt to Equity Ratio

Measures if Citius Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.2% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Citius Pharmaceuticals Inc:

  • The MRQ is 0.142. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.134. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.142TTM0.134+0.008
TTM0.134YOY0.095+0.039
TTM0.1345Y0.160-0.025
5Y0.16010Y0.162-0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1420.393-0.251
TTM0.1340.409-0.275
YOY0.0950.340-0.245
5Y0.1600.438-0.278
10Y0.1620.476-0.314

2. Market Valuation of Citius Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Citius Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Citius Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -3.26 means the investor is paying $-3.26 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Citius Pharmaceuticals Inc:

  • The EOD is -2.993. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.259. Based on the earnings, the company is expensive. -2
  • The TTM is -4.012. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.993MRQ-3.259+0.266
MRQ-3.259TTM-4.012+0.752
TTM-4.012YOY-7.078+3.066
TTM-4.0125Y-9.013+5.002
5Y-9.01310Y-19.249+10.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.993-2.403-0.590
MRQ-3.259-2.596-0.663
TTM-4.012-2.763-1.249
YOY-7.078-4.011-3.067
5Y-9.013-6.398-2.615
10Y-19.249-6.544-12.705
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Citius Pharmaceuticals Inc:

  • The EOD is -4.504. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.904. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.953. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.504MRQ-4.904+0.401
MRQ-4.904TTM-4.953+0.049
TTM-4.953YOY-6.556+1.602
TTM-4.9535Y-9.172+4.219
5Y-9.17210Y-21.158+11.986
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.504-3.046-1.458
MRQ-4.904-3.324-1.580
TTM-4.953-3.598-1.355
YOY-6.556-5.424-1.132
5Y-9.172-8.377-0.795
10Y-21.158-9.022-12.136
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Citius Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.41 means the investor is paying $1.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Citius Pharmaceuticals Inc:

  • The EOD is 1.295. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.410. Based on the equity, the company is underpriced. +1
  • The TTM is 1.643. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.295MRQ1.410-0.115
MRQ1.410TTM1.643-0.232
TTM1.643YOY1.710-0.068
TTM1.6435Y3.839-2.197
5Y3.83910Y-5.652+9.491
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2952.052-0.757
MRQ1.4102.122-0.712
TTM1.6432.111-0.468
YOY1.7102.859-1.149
5Y3.8393.576+0.263
10Y-5.6523.978-9.630
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Citius Pharmaceuticals Inc.

3.1. Institutions holding Citius Pharmaceuticals Inc

Institutions are holding 15.05% of the shares of Citius Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc5.31620.000284578146716758.6265
2023-12-31Vanguard Group Inc4.33720.00016900230727301.0653
2023-12-31Geode Capital Management, LLC1.74730.000227799081045333.9072
2023-12-31State Street Corporation1.38750.0001220736148190.2188
2023-12-31Northern Trust Corp0.65690.00011045135-9130-0.866
2023-12-31Advisor Group Holdings, Inc.0.5860.00129322538598471187.5356
2023-12-31Nuveen Asset Management, LLC0.30460.000148464900
2023-12-31Charles Schwab Investment Management Inc0.22440.000135699400
2023-12-31Bank of New York Mellon Corp0.21520.000134232400
2023-12-31Morgan Stanley - Brokerage Accounts0.15330243959167943220.9311
2023-12-31HighTower Advisors, LLC0.12760.0003203019-6179-2.9537
2023-12-31Goldman Sachs Group Inc0.116401851143082319.9772
2023-12-31Inspire Advisors, LLC0.11490.0208182739-3671-1.9693
2023-12-31Bank of America Corp0.113501806167703974.3785
2023-12-31Barclays PLC0.10610.0001168823147037674.9151
2023-09-30Key Bridge Compliance LLC0.09690.0331541301541300
2023-12-31Rhumbline Advisers0.09440.0001150123-1370-0.9043
2023-12-31Susquehanna International Group, LLP0.0886014099191479184.7613
2023-12-31UBS Group AG0.086401375133948940.285
2023-12-31Arkadios Wealth Advisors0.06290.006410000000
Total 15.93630.062925353695+2401194+9.5%

3.2. Funds holding Citius Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Vanguard Total Stock Mkt Idx Inv2.6020.0002413960369200.1674
2024-03-28iShares Russell 2000 ETF2.04730.0045325714415720.0483
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr1.23060.0017195789500
2024-01-31Fidelity Small Cap Index0.74040.003117792800
2024-03-28iShares Russell 2000 Value ETF0.71460.00811136950-721-0.0634
2024-02-29Fidelity Extended Market Index0.5140.0016817777-3962-0.4821
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.42790.001468070000
2024-03-31Vanguard Russell 2000 ETF0.31490.00445010225967513.5211
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.28180.004144840000
2024-02-29TIAA-CREF Equity Index Instl0.20110.000632000000
2023-12-31NT R2000 Index Fund - NL0.19890.0033316406-54430-14.6776
2024-03-28iShares Micro-Cap ETF0.18330.028529159600
2024-03-31Schwab Small Cap Index0.17660.004128092100
2023-12-31NT R2000 Value Index Fund - NL0.17590.0056279796-55324-16.5087
2023-09-30BlackRock Extended Mkt Composite0.16870.001326841521500.8075
2024-03-31Russell 2000 Index Non-Lendable Fund E0.16540.00462631296824535.0183
2023-12-31NT R2000 Index Fund - DC - NL - 20.15660.0033249173-43991-15.0056
2024-03-31BlackRock Extended Equity Market K0.14530.0014231087830.0359
2024-02-29Fidelity Total Market Index0.14090.000222423100
2023-12-31Northern Trust Russell 2000 Value Index0.13130.006120882000
Total 10.71750.08817050993-19783-0.1%

3.3. Insider Transactions

Insiders are holding 6.823% of the shares of Citius Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2019-09-27Leonard L MazurBUY22347000.9 
2019-09-27Myron Z HolubiakBUY5585970.9 
2019-09-25Myron Z HolubiakBUY50006.02 
2019-04-03Leonard L MazurBUY11650481.558020643
2019-04-03Myron Z HolubiakBUY1294501.55
2018-08-13Myron Z HolubiakBUY7843141.28
2018-03-28Myron Z HolubiakBUY29153.09
2017-08-24Leonard L MazurBUY110002.683337730
2017-08-08Leonard L MazurBUY4214004.131779663

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Citius Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.038-0.025-36%-0.037-4%0.019-299%0.013-386%
Book Value Per Share--0.5360.576-7%0.680-21%0.477+12%0.275+95%
Current Ratio--5.0575.931-15%11.261-55%8.866-43%4.856+4%
Debt To Asset Ratio--0.1240.118+5%0.087+43%0.133-7%0.746-83%
Debt To Equity Ratio--0.1420.134+6%0.095+49%0.160-11%0.162-12%
Dividend Per Share----0%-0%-0%-0%
Eps---0.058-0.060+3%-0.044-24%-0.040-31%-0.026-55%
Free Cash Flow Per Share---0.039-0.048+24%-0.045+16%-0.049+26%-0.029-25%
Free Cash Flow To Equity Per Share---0.039-0.026-33%-0.001-96%-0.025-35%-0.010-74%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.210--------
Intrinsic Value_10Y_min---2.402--------
Intrinsic Value_1Y_max---0.096--------
Intrinsic Value_1Y_min---0.248--------
Intrinsic Value_3Y_max---0.200--------
Intrinsic Value_3Y_min---0.744--------
Intrinsic Value_5Y_max---0.195--------
Intrinsic Value_5Y_min---1.233--------
Market Cap110523302.058-9%120355373.552151573791.497-21%187334371.920-36%201402348.002-40%206490604.096-42%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.295-9%1.4101.643-14%1.710-18%3.839-63%-5.652+501%
Pe Ratio-2.993+8%-3.259-4.012+23%-7.078+117%-9.013+177%-19.249+491%
Price Per Share0.695-9%0.7570.953-21%1.178-36%1.266-40%1.298-42%
Price To Free Cash Flow Ratio-4.504+8%-4.904-4.953+1%-6.556+34%-9.172+87%-21.158+331%
Price To Total Gains Ratio-18.128+8%-19.741-6.591-67%-35.944+82%2.322-950%-177.785+801%
Quick Ratio--3.6474.664-22%10.493-65%8.345-56%4.584-20%
Return On Assets---0.095-0.092-3%-0.059-38%-0.101+6%-0.339+258%
Return On Equity---0.109-0.105-3%-0.064-41%-0.121+11%-0.104-4%
Total Gains Per Share---0.038-0.025-36%-0.037-4%0.019-299%0.013-386%
Usd Book Value--85334634.00091718201.750-7%108247965.250-21%75902202.650+12%43829913.000+95%
Usd Book Value Change Per Share---0.038-0.025-36%-0.037-4%0.019-299%0.013-386%
Usd Book Value Per Share--0.5360.576-7%0.680-21%0.477+12%0.275+95%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.058-0.060+3%-0.044-24%-0.040-31%-0.026-55%
Usd Free Cash Flow---6135310.000-7592770.750+24%-7133543.250+16%-7750853.550+26%-4608481.350-25%
Usd Free Cash Flow Per Share---0.039-0.048+24%-0.045+16%-0.049+26%-0.029-25%
Usd Free Cash Flow To Equity Per Share---0.039-0.026-33%-0.001-96%-0.025-35%-0.010-74%
Usd Market Cap110523302.058-9%120355373.552151573791.497-21%187334371.920-36%201402348.002-40%206490604.096-42%
Usd Price Per Share0.695-9%0.7570.953-21%1.178-36%1.266-40%1.298-42%
Usd Profit---9231185.000-9545113.000+3%-6981620.000-24%-6381104.250-31%-4156066.850-55%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.038-0.025-36%-0.037-4%0.019-299%0.013-386%
 EOD+3 -5MRQTTM+8 -21YOY+6 -235Y+12 -1710Y+9 -20

4.2. Fundamental Score

Let's check the fundamental score of Citius Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.993
Price to Book Ratio (EOD)Between0-11.295
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.647
Current Ratio (MRQ)Greater than15.057
Debt to Asset Ratio (MRQ)Less than10.124
Debt to Equity Ratio (MRQ)Less than10.142
Return on Equity (MRQ)Greater than0.15-0.109
Return on Assets (MRQ)Greater than0.05-0.095
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Citius Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.357
Ma 20Greater thanMa 500.731
Ma 50Greater thanMa 1000.780
Ma 100Greater thanMa 2000.754
OpenGreater thanClose0.710
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets97,400
Total Liabilities12,065
Total Stockholder Equity84,734
 As reported
Total Liabilities 12,065
Total Stockholder Equity+ 84,734
Total Assets = 97,400

Assets

Total Assets97,400
Total Current Assets28,210
Long-term Assets69,190
Total Current Assets
Cash And Cash Equivalents 20,346
Other Current Assets 7,864
Total Current Assets  (as reported)28,210
Total Current Assets  (calculated)28,210
+/-0
Long-term Assets
Property Plant Equipment 405
Goodwill 9,347
Intangible Assets 59,400
Long-term Assets Other 38
Long-term Assets  (as reported)69,190
Long-term Assets  (calculated)69,190
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,579
Long-term Liabilities6,486
Total Stockholder Equity84,734
Total Current Liabilities
Short-term Debt 224
Accounts payable 2,647
Other Current Liabilities 2,708
Total Current Liabilities  (as reported)5,579
Total Current Liabilities  (calculated)5,579
+/-0
Long-term Liabilities
Capital Lease Obligations 429
Long-term Liabilities  (as reported)6,486
Long-term Liabilities  (calculated)429
+/- 6,058
Total Stockholder Equity
Common Stock159
Retained Earnings -171,463
Other Stockholders Equity 256,038
Total Stockholder Equity (as reported)84,734
Total Stockholder Equity (calculated)84,734
+/-0
Other
Capital Stock159
Cash and Short Term Investments 20,346
Common Stock Shares Outstanding 158,956
Liabilities and Stockholders Equity 97,400
Net Debt -19,917
Net Invested Capital 84,734
Net Working Capital 22,631
Property Plant and Equipment Gross 405
Short Long Term Debt Total 429



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-31
> Total Assets 
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
1,557
823
766
962
742
347
24,779
23,014
21,950
21,482
21,335
21,567
24,417
28,473
26,064
23,826
31,051
28,078
24,236
25,545
28,986
24,983
26,493
38,400
43,774
35,312
134,666
146,593
142,429
137,516
127,786
120,316
113,999
111,705
104,241
110,405
103,611
97,400
97,400103,611110,405104,241111,705113,999120,316127,786137,516142,429146,593134,66635,31243,77438,40026,49324,98328,98625,54524,23628,07831,05123,82626,06428,47324,41721,56721,33521,48221,95023,01424,7793477429627668231,557006000000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
1,552
817
760
957
736
341
3,780
2,021
893
490
343
557
3,424
7,482
5,073
2,835
10,060
7,088
3,246
4,557
7,942
2,835
4,393
8,569
13,982
5,579
104,974
116,935
72,814
67,945
58,259
50,835
44,564
42,317
34,901
41,114
34,370
28,210
28,21034,37041,11434,90142,31744,56450,83558,25967,94572,814116,935104,9745,57913,9828,5694,3932,8357,9424,5573,2467,08810,0602,8355,0737,4823,4245573434908932,0213,7803417369577608171,552006000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,552
817
760
951
676
281
3,759
1,626
294
47
61
199
3,204
7,371
5,008
2,762
9,184
7,041
3,199
4,511
7,894
2,780
4,339
8,517
13,860
4,296
103,697
115,664
70,073
65,421
55,756
48,044
41,712
36,887
29,066
33,282
26,481
20,346
20,34626,48133,28229,06636,88741,71248,04455,75665,42170,073115,664103,6974,29613,8608,5174,3392,7807,8944,5113,1997,0419,1842,7625,0087,3713,20419961472941,6263,7592816769517608171,552000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
818
818
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000008188180000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
6
60
60
21
394
598
444
282
358
220
111
65
73
58
47
47
47
48
56
54
52
122
1,283
1,277
1,271
2,741
2,524
2,503
2,790
2,853
5,430
5,836
7,832
7,890
7,864
7,8647,8907,8325,8365,4302,8532,7902,5032,5242,7411,2711,2771,283122525456484747475873651112203582824445983942160606000006000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
20,999
20,993
21,058
20,992
20,991
21,011
20,992
20,992
20,991
20,991
20,990
20,990
20,990
20,988
21,044
22,147
22,100
29,831
29,792
29,733
29,692
29,657
69,615
69,571
69,527
69,481
69,435
69,388
69,340
69,291
69,241
69,190
69,19069,24169,29169,34069,38869,43569,48169,52769,57169,61529,65729,69229,73329,79229,83122,10022,14721,04420,98820,99020,99020,99020,99120,99120,99220,99221,01120,99120,99221,05820,99320,999555555000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
4
4
3
2
2
3
3
2
2
1
1
1
1
1
1,104
1,056
1,027
988
948
907
873
830
786
742
696
650
603
555
506
456
405
4054565065556036506967427868308739079489881,0271,0561,104111112233223445000000000000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
1,587
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,347
9,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,3471,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,5871,587000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
19,405
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
19,400
59,400
59,400
59,400
59,400
59,400
59,400
59,400
59,400
59,400
59,400
59,40059,40059,40059,40059,40059,40059,40059,40059,40059,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,40019,405555555000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
6
6
6
20,994
20,989
21,053
20,989
20,989
21,008
20,990
20,988
2
2
2
2
2
0
57
57
57
57
57
38
38
38
38
38
38
38
38
38
0
38
0
0
00380383838383838383838575757575702222220,98820,99021,00820,98920,98921,05320,98920,994666660000000000000000
> Total Liabilities 
0
0
21
24
24
34
41
46
46
58
62
15
15
25
31
2,299
1,646
1,684
2,143
1,377
1,937
4,353
4,854
5,184
6,319
7,342
9,973
2,469
2,617
2,562
2,190
3,185
3,900
3,361
4,038
4,608
4,606
4,049
9,658
10,103
9,511
8,904
9,311
9,646
12,958
9,590
9,980
10,573
10,672
12,434
12,105
12,180
12,065
12,06512,18012,10512,43410,67210,5739,9809,59012,9589,6469,3118,9049,51110,1039,6584,0494,6064,6084,0383,3613,9003,1852,1902,5622,6172,4699,9737,3426,3195,1844,8544,3531,9371,3772,1431,6841,6462,2993125151562584646413424242100
   > Total Current Liabilities 
0
0
21
24
24
34
41
46
46
58
62
15
15
25
31
2,299
1,646
1,684
2,143
1,377
1,937
4,353
4,854
5,184
6,319
7,342
9,973
2,469
2,617
2,562
2,190
3,185
3,900
3,361
4,038
4,608
3,630
3,112
3,610
4,097
3,548
2,985
3,600
3,982
7,342
4,022
4,461
4,530
4,537
6,210
5,791
5,779
5,579
5,5795,7795,7916,2104,5374,5304,4614,0227,3423,9823,6002,9853,5484,0973,6103,1123,6304,6084,0383,3613,9003,1852,1902,5622,6172,4699,9737,3426,3195,1844,8544,3531,9371,3772,1431,6841,6462,2993125151562584646413424242100
       Short-term Debt 
0
0
13
18
18
27
33
17
17
27
52
3
3
24
29
600
1,390
1,245
1,717
739
873
773
173
673
1,493
2,023
5,416
173
173
173
173
173
173
173
173
173
319
323
328
332
336
341
337
177
182
187
192
197
202
207
213
218
224
2242182132072021971921871821773373413363323283233191731731731731731731731731735,4162,0231,4936731737738737391,7171,2451,39060029243352271717332718181300
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
739
0
0
0
673
911
426
5,416
173
173
173
173
0
0
173
173
173
173
173
173
173
173
173
165
0
0
0
0
0
0
0
0
0
0
0000000000165173173173173173173173173173001731731731735,4164269116730007390000000000000000000
       Accounts payable 
0
0
1
1
1
1
1
0
1
0
0
11
11
0
1
106
199
343
334
559
459
367
309
909
986
1,863
1,978
602
561
1,400
912
1,573
2,083
1,926
2,431
2,714
1,547
1,524
1,812
1,856
984
1,133
1,355
1,277
1,789
1,705
1,691
1,165
1,538
2,726
3,080
2,927
2,647
2,6472,9273,0802,7261,5381,1651,6911,7051,7891,2771,3551,1339841,8561,8121,5241,5472,7142,4311,9262,0831,5739121,4005616021,9781,86398690930936745955933434319910610111100101111100
       Other Current Liabilities 
0
0
7
5
5
6
6
29
29
30
10
0
0
0
1
1,451
1,447
1,340
1,808
818
1,478
1,503
2,948
1,682
911
426
581
1,694
1,883
988
1,105
1,438
1,644
1,262
1,434
1,721
1,763
1,264
1,471
1,909
2,227
1,511
1,909
2,528
5,370
2,130
2,579
3,168
2,797
3,277
2,498
2,633
2,708
2,7082,6332,4983,2772,7973,1682,5792,1305,3702,5281,9091,5112,2271,9091,4711,2641,7631,7211,4341,2621,6441,4381,1059881,8831,6945814269111,6822,9481,5031,4788181,8081,3401,4471,4511000103029296655700
   > Long-term Liabilities 
0
0
14
0
19
28
34
0
17
27
52
0
15
25
31
706
199
343
334
559
459
1,140
482
1,582
2,479
3,886
7,394
775
734
1,573
1,085
1,746
2,256
2,099
2,604
2,887
976
937
6,048
6,006
5,963
5,920
5,711
5,664
5,617
5,568
5,519
6,043
6,134
6,225
6,314
6,401
6,486
6,4866,4016,3146,2256,1346,0435,5195,5685,6175,6645,7115,9205,9636,0066,0489379762,8872,6042,0992,2561,7461,0851,5737347757,3943,8862,4791,5824821,1404595593343431997063125150522717034281901400
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
165
165
165
165
0
0
0
0
0
0
0
0
0
0
0
0000000000016516516516500000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,986
4,986
4,986
4,986
4,986
4,986
4,986
4,986
4,986
5,562
5,706
0
5,994
0
0
005,99405,7065,5624,9864,9864,9864,9864,9864,9864,9864,9864,98600000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
0
0
20
0
0
0
0
0
0
0
0
0
0
0
4,986
4,986
4,986
4,986
4,986
4,986
4,986
4,986
4,986
5,562
5,706
5,850
5,994
0
0
005,9945,8505,7065,5624,9864,9864,9864,9864,9864,9864,9864,9864,9860000000000020006500000000000000000000000
> Total Stockholder Equity
0
0
-21
-24
-24
-34
-40
-46
-46
-57
-62
-15
-15
-25
-31
-742
-824
-918
-1,180
-635
-1,590
20,426
18,160
16,766
15,164
13,992
11,594
21,947
25,856
23,502
21,635
27,866
24,178
20,875
21,507
24,379
20,377
22,444
28,742
33,671
25,200
125,162
136,682
132,182
123,958
117,596
109,736
102,826
100,433
91,206
97,700
90,831
84,734
84,73490,83197,70091,206100,433102,826109,736117,596123,958132,182136,682125,16225,20033,67128,74222,44420,37724,37921,50720,87524,17827,86621,63523,50225,85621,94711,59413,99215,16416,76618,16020,426-1,590-635-1,180-918-824-742-31-25-15-15-62-57-46-46-40-34-24-24-2100
   Common Stock
0
0
18
18
18
18
18
18
18
18
18
18
18
18
18
30
31
32
33
34
35
71
73
73
74
76
5
8
10
11
11
16
18
19
22
29
30
38
46
56
56
135
146
146
146
146
146
146
146
146
159
159
159
159159159146146146146146146146146135565646383029221918161111108576747373713534333231301818181818181818181818181800
   Retained Earnings Total Equity00-152,287-143,808-133,282-129,688-121,698-112,834-105,273-96,048-91,087-85,263-81,140-70,594-66,473-64,567-60,142-55,820-52,170-47,764-44,133-40,258-37,411-35,389-30,967-27,721-24,678-22,256-19,512-17,336-14,747-11,131-10,261-9,041-8,132-7,307-6,9620-112-106-96-9500000000-3900
   Accumulated Other Comprehensive Income 0000000000000000000000-9-9-8-7-7-6-5-5-4-3000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
63
63
63
63
0
6,107
6,358
6,919
8,371
8,636
31,485
32,834
34,029
34,602
36,172
36,267
49,660
56,814
58,880
59,035
68,107
68,293
68,621
73,655
80,170
80,489
86,973
95,169
104,209
106,285
210,290
227,622
228,084
229,085
230,284
231,287
232,368
233,569
234,868
249,828
0
0
00249,828234,868233,569232,368231,287230,284229,085228,084227,622210,290106,285104,20995,16986,97380,48980,17073,65568,62168,29368,10759,03558,88056,81449,66036,26736,17234,60234,02932,83431,4858,6368,3716,9196,3586,10706363636300000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
34
0
0
0
0
0
63
63
63
63
5,366
6,107
6,358
6,919
8,371
8,636
31,485
32,834
34,029
34,602
36,172
36,267
49,660
56,814
58,880
59,035
68,107
68,293
68,621
73,655
80,170
80,489
86,973
95,169
104,209
106,285
210,290
227,622
228,084
229,085
230,284
231,287
232,368
233,569
234,868
249,828
252,904
256,038
256,038252,904249,828234,868233,569232,368231,287230,284229,085228,084227,622210,290106,285104,20995,16986,97380,48980,17073,65568,62168,29368,10759,03558,88056,81449,66036,26736,17234,60234,02932,83431,4858,6368,3716,9196,3586,1075,36663636363000003400000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-09-30)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-194
Gross Profit-194-194
 
Operating Income (+$)
Gross Profit-194
Operating Expense-36,732
Operating Income-36,732-36,926
 
Operating Expense (+$)
Research Development14,820
Selling General Administrative21,912
Selling And Marketing Expenses0
Operating Expense36,73236,732
 
Net Interest Income (+$)
Interest Income1,179
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,179
 
Pretax Income (+$)
Operating Income-36,732
Net Interest Income1,179
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-31,967-40,318
EBIT - interestExpense = -36,732
-31,967
-32,543
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-36,732-31,967
Earnings Before Interest and Taxes (EBITDA)-36,538
 
After tax Income (+$)
Income Before Tax-31,967
Tax Provision-576
Net Income From Continuing Ops-32,543-32,543
Net Income-32,543
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses36,732
Total Other Income/Expenses Net3,586-1,179
 

Technical Analysis of Citius Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Citius Pharmaceuticals Inc. The general trend of Citius Pharmaceuticals Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Citius Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Citius Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.04 < 1.05 < 1.07.

The bearish price targets are: 0.65 > 0.64 > 0.6.

Tweet this
Citius Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Citius Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Citius Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Citius Pharmaceuticals Inc. The current macd is -0.03286613.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Citius Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Citius Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Citius Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Citius Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCitius Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Citius Pharmaceuticals Inc. The current adx is 14.59.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Citius Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Citius Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Citius Pharmaceuticals Inc. The current sar is 0.849978.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Citius Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Citius Pharmaceuticals Inc. The current rsi is 43.36. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Citius Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCitius Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Citius Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Citius Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Citius Pharmaceuticals Inc Daily Stochastic Oscillator ChartCitius Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Citius Pharmaceuticals Inc. The current cci is -75.61710085.

Citius Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCitius Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Citius Pharmaceuticals Inc. The current cmo is -14.38539321.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Citius Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCitius Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Citius Pharmaceuticals Inc. The current willr is -65.72681704.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Citius Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Citius Pharmaceuticals Inc Daily Williams %R ChartCitius Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Citius Pharmaceuticals Inc. The current atr is 0.0698969.

Citius Pharmaceuticals Inc Daily Average True Range (ATR) ChartCitius Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Citius Pharmaceuticals Inc. The current obv is -39,083,194.

Citius Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCitius Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Citius Pharmaceuticals Inc. The current mfi is 22.86.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Citius Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCitius Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Citius Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Citius Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Citius Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.357
Ma 20Greater thanMa 500.731
Ma 50Greater thanMa 1000.780
Ma 100Greater thanMa 2000.754
OpenGreater thanClose0.710
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Citius Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Citius Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Citius Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Citius Pharmaceuticals Inc

I send you an email if I find something interesting about Citius Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Citius Pharmaceuticals Inc.

Receive notifications about Citius Pharmaceuticals Inc in your mailbox!